Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Piotrowski, Wojciech J.; Bestry, Iwona; Białas, Adam J.; Boros, Piotr; Grzanka, Piotr; Jassem, Ewa; Jastrzębski, Dariusz; Klimczak, Dariusz Piotr; Langfort, Renata; Lewandowska, Katarzyna; Majewski, Sebastian; Martusewicz-Boros, Magdalena; Onisch, Karina; Puścińska, Elżbieta; Siemińska, Alicja; Sobiecka, Małgorzata; Szołkowska, Małgorzata; Wiatr, Elżbieta; Wilczyński, Gracjan; Kuś, Jan

doi:10.5603/arm.2020.0081

Cited by 21 publications

(39 citation statements)

References 361 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 12 included CPGs (11 CPGs published in journals and 1 on the NICE website) were published between 2013 and 2020 (2,(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). All were developed by local or international medical societies.…”

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

“…All were developed by local or international medical societies. Two CPGs (2,23) were globally developed, and the others came from nine different countries: France, Germany, Spain, Switzerland, Japan, Korea, England, Brazil, and Poland (24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Six CPGs (24,26,28,30,31,33) covered the diagnosis and treatment of IPF, five referred to treatment (23,25,27,29,32), and one referred to diagnosis (2).…”

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

“…Two CPGs (2,23) were globally developed, and the others came from nine different countries: France, Germany, Spain, Switzerland, Japan, Korea, England, Brazil, and Poland (24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Six CPGs (24,26,28,30,31,33) covered the diagnosis and treatment of IPF, five referred to treatment (23,25,27,29,32), and one referred to diagnosis (2). Six CPGs were updated and developed from original guidelines (2,(23)(24)(25)27,31), three were adapted from other guidelines (26,28,30), and the remaining three were original versions (2,32,33).…”

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

See 2 more Smart Citations

Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis

Xie

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Clinical practice guidelines (CPGs) have long served as an essential tool for clinicians to rationalize their treatment in practice. However, the quality of guidelines varies greatly. The present study aimed to analyze high-quality CPGs of idiopathic pulmonary fibrosis (IPF) and highlight the potential for further improvement. Methods: Three guideline developers' websites, PubMed, Embase, and Web of Science, as well as a public search engine, Google Scholar, were searched to retrieve CPGs regarding the management of IPF. The methodology and reporting quality of retrieved CPGs were assessed using the validated Appraisal of Guidelines for Research and Evaluation Instrument II (AGREE II) and Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. Results: Twelve IPF CPGs were reviewed, among which 7 (58.3%) were considered as "recommended" and 1 (8.3%) as "recommended with modifications". Among the 6 domains of AGREE II, scope and purpose (70.99%) and clarity of presentation (68.06%) were considered to be the fields in which CPGs performed best, evidenced by the highest mean AGREE II scores. The domains in which the reviewed CPGs received the lowest mean scores were rigor of development (50.87%) and applicability (34.14%). The intraclass correlation coefficient scores were excellent in each domain. The basic information domain received the highest overall reporting rate in the 7 domains of the RIGHT checklist; the other 6 domains had a full reporting rate of <50%. Eight items had a satisfactory level of reporting, whereas 14 items had poor reporting according to the RIGHT checklist. Correlation analysis revealed a highly positive correlation between the methodology and reporting quality of CPGs for IPF (r=0.872). Conclusions: The methodological quality of selected IPF CPGs fluctuated greatly, and the full reporting rate was found to be quite low in some domains. In the future, we should focus not only on improving the methodological quality in the development of guidelines, but also on the reporting quality of guidelines.

show abstract

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

Section: Characteristics Of Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis

Xie

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…However, in clinical practice, IPF is probably the second most common ILD and the most frequent idiopathic interstitial pneumonia (IIP) with a chronic, fibrosing course. It is estimated that the annual incidence of IPF in Poland is approximately 1600-1800 cases, and the prevalence is about 5000-6000 [1].…”

Section: Introductionmentioning

confidence: 99%

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Martusewicz-Boros¹,

Górska

2020

Advances in Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a rare disease with progressive course and a very unfavourable prognosis. Antifibrotic drugs are a chance to reduce the rate of disease progression and extend the life of IPF patients. One of these drugs is nintedanib, an oral tyrosine kinase inhibitor. In the following article, the reader will find a summary of current knowledge on the efficacy and safety of nintedanib treatment of IPF patients. This study uses data from pivotal studies and experience from everyday clinical practice indicating a wide range of possible applications of the drug in IPF patients.

show abstract

“…The symptoms usually appear insidiously and many patients are unable to pinpoint the date of their appearance. It is important to note that deteriorating exercise tolerance often fails to alarm patients about the early stages of IPF because these patients tend to attribute their symptoms to the ageing process or treat them as a consequence of long-term tobacco smoking [10].…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Value of Fixed Time and Self-Paced Walking Tests in Patients Diagnosed with Idiopathic Pulmonary Fibrosis

Białas

Iwański

Miłkowska-Dymanowska

et al. 2020

Advances in Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial pneumonia that has an unknown etiology. The natural history of the disease is characterized by a progressive decline in pulmonary function and overall health and well-being. The median survival time is between 2-3 years; however, the disease course is variable and unpredictable. The twelve-minute walking test (12MWT) and six-minute walking test (6MWT) are two fixed time tests that are commonly used in clinical practice. Our short and clinically oriented narrative review attempted to summarize current evidence supporting the use of fixed time, self-paced walking tests in predicting the outcome of patients diagnosed with IPF. A number of studies have justified that the 6MWT is a simple, cost-effective, well documented, fixed time, and self-paced walking test which is a valid and reliable measure of disease status and can also be used as a prognostic tool in patients with IPF. However, there is a need for dedicated and validated reference equations for this population of patients. It is also necessary to fill the knowledge gap about the role of the 12MWT. We hypothesize that it would be useful in evaluating patients that are in the early stages of the disease.

show abstract

Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Abstract: Wojciech J. Piotrowski et al., Diagnosis and treatment of idiopathic pulmonary fibrosis 43 www.journals.viamedica.pl

Cited by 21 publications

References 361 publications

Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis

Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis

Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

The Prognostic Value of Fixed Time and Self-Paced Walking Tests in Patients Diagnosed with Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About